EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Adicet Bio's enterprise value is $-74.57 Mil.
Adicet Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-110.82 Mil. Therefore, Adicet Bio's EV-to-EBITDA for today is 0.67.
The historical rank and industry rank for Adicet Bio's EV-to-EBITDA or its related term are showing as below:
ACET'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.3 Med: -0.22 Max: 3.19
Current: 0.67
During the past 7 years, the highest EV-to-EBITDA of Adicet Bio was 3.19. The lowest was -20.30. And the median was -0.22.
ACET's EV-to-EBITDA is ranked better than 72.26% of 501
companies
in the Biotechnology industry
Industry Median: 7.89
vs ACET: 0.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Adicet Bio EV-to-EBITDA Historical Data
The historical data trend for Adicet Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Adicet Bio's EV-to-EBITDA
For the Biotechnology subindustry, Adicet Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adicet Bio's EV-to-EBITDA falls into.
Adicet Bio's current Enterprise Value is $-74.57 Mil.
Adicet Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-110.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (NAS:ACET) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adicet Bio's share price for today is $0.6921.
Adicet Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Adicet Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACET has been successfully added to your 